Plain-English translation of NCT03734952 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether patients with esophageal squamous cell carcinoma benefit from receiving additional radiation therapy after surgery. All participants first receive chemotherapy and radiation, then have surgery to remove the tumor. Half the patients will then receive extra radiation therapy after surgery, while the other half will not. Researchers want to see if this additional treatment helps people live longer and reduces the cancer from coming back.
Even with chemotherapy, radiation, and surgery, many patients with this type of esophageal cancer experience the cancer returning. Doctors believe that adding extra radiation after surgery may help kill any remaining cancer cells and prevent recurrence, potentially improving survival.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy combined with radiation therapy to shrink your tumor. After this, you will undergo surgery to remove the affected portion of your esophagus. Then you will be randomly assigned to either receive additional radiation therapy or no further radiation. You will be followed for at least 5 years after starting treatment, with regular visits to monitor your health, check for cancer recurrence, and assess how well you are surviving.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Sponsor
Fujian Medical University Union Hospital
Enrollment target
~537 participants
Started
May 2023
Primary completion
January 2029
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Benhua Xu, doctor
Fujian Medical University Union Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.